Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Picard

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Pharmaceutics|July 3, 2021
Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposomeAlexandrine L Martel, Nya L Fraleigh, Emilie Picard, et al.
International Journal of Molecular Sciences|November 11, 2022
Neuroprotective Effects of Transferrin in Experimental Glaucoma ModelsJenny Youale, Karine Bigot, Bindu Kodati, et al.
Journal of Proteome Research|May 21, 2025
Metabolomic Signature in Men with Central Serous Chorioretinopathy Using UHPLC-MSStephanie Durand, Marta Zola, Elodie Bousquet, et al.
Journal of Proteome Research|February 5, 2026
Proteomic Signature in Men with Central Serous ChorioretinopathyChristophe Chambon, Emilie Picard, Marta Zola, et al.
Aging|November 25, 2010
CD36 plays an important role in the clearance of oxLDL and associated age-dependent sub-retinal depositsEmilie Picard, Marianne Houssier, Kim Bujold, et al.
Cell Death & Disease|October 6, 2025
Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD)Jenny Youale, Karine Bigot, Thara Jaworski, et al.
Oncoimmunology|April 11, 2018
SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contextsMarie Kroemer, Laurie Spehner, Patricia Mercier-Letondal, et al.
Science Advances|January 22, 2019
Iron is neurotoxic in retinal detachment and transferrin confers neuroprotectionAlejandra Daruich, Quentin Le Rouzic, Laurent Jonet, et al.
Pharmaceutics|August 10, 2021
Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat ModelMarianne Berdugo, Kimberley Delaunay, Cécile Lebon, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 4, 2021
Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo ModelAlejandra Daruich, Thara Jaworski, Hugues Henry, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Pharmaceutics|July 3, 2021
Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposomeAlexandrine L Martel, Nya L Fraleigh, Emilie Picard, et al.
International Journal of Molecular Sciences|November 11, 2022
Neuroprotective Effects of Transferrin in Experimental Glaucoma ModelsJenny Youale, Karine Bigot, Bindu Kodati, et al.
Journal of Proteome Research|May 21, 2025
Metabolomic Signature in Men with Central Serous Chorioretinopathy Using UHPLC-MSStephanie Durand, Marta Zola, Elodie Bousquet, et al.
Journal of Proteome Research|February 5, 2026
Proteomic Signature in Men with Central Serous ChorioretinopathyChristophe Chambon, Emilie Picard, Marta Zola, et al.
Aging|November 25, 2010
CD36 plays an important role in the clearance of oxLDL and associated age-dependent sub-retinal depositsEmilie Picard, Marianne Houssier, Kim Bujold, et al.
Cell Death & Disease|October 6, 2025
Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD)Jenny Youale, Karine Bigot, Thara Jaworski, et al.
Oncoimmunology|April 11, 2018
SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contextsMarie Kroemer, Laurie Spehner, Patricia Mercier-Letondal, et al.
Science Advances|January 22, 2019
Iron is neurotoxic in retinal detachment and transferrin confers neuroprotectionAlejandra Daruich, Quentin Le Rouzic, Laurent Jonet, et al.
Pharmaceutics|August 10, 2021
Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat ModelMarianne Berdugo, Kimberley Delaunay, Cécile Lebon, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 4, 2021
Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo ModelAlejandra Daruich, Thara Jaworski, Hugues Henry, et al.
Pageof 5